The role of antibodies against hsp90 in the treatment of fungal infections.
Advances in antibody engineering have solved many of the problems inherent in traditional sources of antibodies, and about a quarter of all biotechnology-based drugs now in development are antibodies. This has come at a time when it is apparent that reliance on antibiotics alone is beginning to select out resistant pathogens, fungi being a prime example. The development of antibody-based therapeutics, such as Mycograb, against novel fungal targets offers a new approach to combating the spread of resistance and reducing mortality.
Burnie
James
J
University of Manchester, Manchester United Kingdom. james.burnie@cmmc.nhs.uk
Matthews
Ruth
R
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D002176:Candida albicans / Q000276:immunology; D002177:Candidiasis / Q000188:drug therapy / Q000276:immunology; D018841:HSP90 Heat-Shock Proteins / Q000276:immunology*; D006801:Humans; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology
D000906:Antibodies; D000935:Antifungal Agents; D018841:HSP90 Heat-Shock Proteins